ADVANZ PHARMA provided earnings guidance for the fourth quarter of 2020. Looking ahead to the fourth quarter, the company anticipates that forecasting its business will continue to be challenging given the ongoing COVID-19 pandemic and the U.K.'s planned exit from the EU at the end of the year 2020. Having said that, the company anticipates that its fourth quarter of 2020 financial results will be in line with the company’s expectations as the company remain ready to respond to fluctuations in market dynamics that could result from COVID-19 or Brexit.